Who was studied, and how
Six numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 23 other studies
1,363people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
metformin
control
Lowered glucose−1.78
Lowered CRP−0.60
Lowered insulin resistance−0.45
randomisedthe abstract, start to end
… significant reduction in insulin (WMD: - 0.99 U/ml, 95% CI - 1.66, - 0.33), glucose (WMD: - 1.78 ml/dl, 95% CI - 2.96, - 0.60), CRP (WMD: - 0.60 mg/l, 95% CI - 0.88, - 0.33), HOMA-IR (WMD: - 0.45, 95% CI - 0.77, - 0.11), leptin (WMD: - 2.44 ng/ml, 95% CI - 3.28, - 1.61), BMI (WMD: - 0.55 kg/m CONCLUSIONS: Breast cancer …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Insulinmetformin vs control
−0.99−1.66 to −0.33
Glucosemetformin vs control
−1.78−2.96 to −0.60
CRPmetformin vs control
−0.60−0.88 to −0.33
HOMA-IRmetformin vs control
−0.45−0.77 to −0.11
Leptinmetformin vs control
−2.44−3.28 to −1.61
BMImetformin vs control
−0.55
MetforminGlycemic controlBody weight & compositionInflammation & biomarkers
Metformin × glycemic controlhelps?replicated
unlikelylikely
0.84not counted
Metformin × inflammation & biomarkershelps?one trial
unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
1 / 7